[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types].

Study findings

Subjective and objective responses to Ladasten and placebo differed across EEG-defined neurasthenia subgroups. Higher subjective responses were not confined to active treatment.

Population and setting

Patients; see abstract scope

Evidence type

Human comparative study

Preparation

See the original report; formulation details require verification.

Source language

rus

Title source

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

Study limitations

• Original full text and detailed methods have not been reviewed.
• Sample size, allocation, masking and numerical outcomes require full-text appraisal; the report cannot establish effects in healthy users.
• Possible overlap with other Ladasten neurasthenia reports, including the existing clinical program, remains unresolved; do not count this as independent replication.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed citation and English abstract checked.

Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.

Open original source or index record ↗

Citation and original source

Original source: Neznamov GG, Bochkarev VK, Reutova MA, Shabanova AA, Siuniakov SA. [Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types]. Eksperimental'naia i klinicheskaia farmakologiia; 2012 2012.

Molekul research summary: https://molekul.io/research/brom-extra-22834121. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles